A recent JAMA Oncology study shows that GLP-1 medications (liraglutide, semaglutide, tirzepatide) may reduce cancer risk in adults with obesity by 17%. The greatest reductions were seen in endometrial, ovarian, and meningioma cancers. AACE President Scott D. Isaacs, MD, FACP, FACE, explains that these findings highlight the role of metabolic dysfunction, particularly MASLD, as a key driver of cancer risk. Therapies like semaglutide have already demonstrated efficacy in reversing MASLD/MASH, establishing their role as foundational treatments in the evolving landscape of metabolic medicine.